Essential phospholipids for nonalcoholic fatty liver disease associated with metabolic syndrome: A systematic review and network meta-analysis

Figure 2 Results of the direct meta-analyses (random effects model) of randomized controlled trials comparing essential phospholipids + antidiabetic therapy with antidiabetic therapy (control). A: Change in alanine aminotransferase levels; B: Change in triglyceride levels; C: Change in total cholesterol levels; D: Relative risk of recovery; E: Relative risk of change in disease; F: Relative risk of final disease severity. EPL: Essential phospholipids; MD: Mean difference; CI: Confidence interval; RE: Random effects; RR: Relative risk; ALT: Alanine aminotransferase.